FDA Determines Regulatory Review Period for Nuzyra Injection Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for Nuzyra Injection, a new drug application submitted to extend a patent claiming the human drug product Nuzyra Injection.